Current Report Filing (8-k)
May 17 2017 - 4:17PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report Pursuant to Section 13 or 15(d) of
the Securities Act of 1934
Date of Report (Dat
e of earliest event reported): May 17, 2017
Omega Protein Corporation
(Exact name of registrant as specified in its charter)
Nevada
(State or other jurisdiction
of incorporation)
|
001-14003
(Commission
File Number)
|
76-0562134
(I.R.S. Employer
Identification No.)
|
|
|
|
|
|
|
|
|
|
210
5
City
West Blvd., Suite 500
Houston
, Texas
(Address of principal executive offices)
|
770
42
(Zip Code)
|
(713) 623-0060
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CRF 240.133-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
[ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
[ ]
Item 7.01 Regulation FD Disclosure
The Company makes and may continue to make presentations to investors, potential investors, analysts and other groups and may utilize presentation material about the Company and its industry. The Company is filing herewith a copy of this presentation material as Exhibit 99.1.
In accordance with General Instructions B.2 and B.6 of Form 8-K, the foregoing information, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall such information and Exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in such a filing.
Item
9.01
Financial
Statements and Exhibits
|
(a)
|
Financial Statements of business acquired.
|
None.
|
(b)
|
Pro Forma
Financial Information.
|
None.
|
(c)
|
Shell Company Transactions.
|
None.
|
99.1
|
Omega Protein Corporation Inve
stor Presentation (May 2017)
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
Omega Protein Corporation
|
|
|
|
|
Dated:
May 17, 2017
|
/s/John D. Held
|
|
|
John D. Held
Executive Vice President and General Counsel
|
Omega Protein (NYSE:OME)
Historical Stock Chart
From Mar 2024 to Apr 2024
Omega Protein (NYSE:OME)
Historical Stock Chart
From Apr 2023 to Apr 2024